[go: up one dir, main page]

PE20091675A1 - Farmaco de combinacion para tratar trastornos vasculares - Google Patents

Farmaco de combinacion para tratar trastornos vasculares

Info

Publication number
PE20091675A1
PE20091675A1 PE2009000377A PE2009000377A PE20091675A1 PE 20091675 A1 PE20091675 A1 PE 20091675A1 PE 2009000377 A PE2009000377 A PE 2009000377A PE 2009000377 A PE2009000377 A PE 2009000377A PE 20091675 A1 PE20091675 A1 PE 20091675A1
Authority
PE
Peru
Prior art keywords
combination drug
vascular disorders
carbostrile
carnitine
salt
Prior art date
Application number
PE2009000377A
Other languages
English (en)
Inventor
Takao Urabe
Yuji Ueno
Kensuke Orito
Hiroshi Ohno
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PE20091675A1 publication Critical patent/PE20091675A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMBINACION DE QUE COMPRENDE: A) CARBOSTIRILO DE FORMULA I, DONDE A ES UN ALQUILENO INFERIOR; R ESCICLOALQUILO; EL ENLACE ENTRE LAS POSICIONES 3 Y 4 DEL ESQUELETO CARBOSTRILO ES UN ENLACE SIMPLE O DOBLE, O UNA SAL DE LA MISMA; B) CARNITINA O UNA SAL DE LA MISMA TAL COMO L-CARNITINA O CLORURO DE LEVOCARNITINA. UN DERIVADO CARBOSTRILO PREFERIDO ES 6-[4-(1-CICLOHEXIL-1H-TETRAZOL-5-IL)BUTOXI]-3,4-DIHIDROCARBOSTIRILO. DICHA COMBINACION EXHBE ACCION SINERGICA Y BAJA TOXICIDAD SIENDO UTIL EN EL TRATAMIENTO DE DE ENFERMEDAD ARTERIAL PERIFERICA OCLUSIVA, ATAQUE ISQUEMICO TRANSITORIO, HEMORRAGIA SUBARACNOIDEA, ENTRE OTROS
PE2009000377A 2008-03-14 2009-03-13 Farmaco de combinacion para tratar trastornos vasculares PE20091675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008065448 2008-03-14
JP2008118289 2008-04-30

Publications (1)

Publication Number Publication Date
PE20091675A1 true PE20091675A1 (es) 2009-11-16

Family

ID=41065644

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000377A PE20091675A1 (es) 2008-03-14 2009-03-13 Farmaco de combinacion para tratar trastornos vasculares

Country Status (14)

Country Link
US (2) US8980919B2 (es)
EP (1) EP2254578A2 (es)
JP (2) JP5574989B2 (es)
KR (1) KR101632448B1 (es)
CN (2) CN104906097A (es)
AR (1) AR070816A1 (es)
AU (1) AU2009224214B2 (es)
BR (1) BRPI0909291A8 (es)
CA (1) CA2717351A1 (es)
CL (1) CL2009000589A1 (es)
PE (1) PE20091675A1 (es)
RU (1) RU2506950C2 (es)
TW (1) TW200944204A (es)
WO (1) WO2009113741A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933205B (zh) 2010-04-28 2014-08-13 诺弗米克斯有限公司 西洛他唑共晶和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
AU1295700A (en) * 1998-11-26 2000-06-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
DE60103668T2 (de) * 2001-02-07 2005-06-09 Disa Industries A/S Sandgiessmaschine mit verbessertem sandblasen
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
PT1942895E (pt) * 2005-09-15 2012-03-29 Otsuka Pharma Co Ltd Fármaco de combinação contendo probucol e um derivado de tetrazolilalcoxi-di-hidrocarboestirilo com efeitos supressores de superóxido

Also Published As

Publication number Publication date
JP2011513480A (ja) 2011-04-28
RU2506950C2 (ru) 2014-02-20
KR20100123909A (ko) 2010-11-25
KR101632448B1 (ko) 2016-06-21
CA2717351A1 (en) 2009-09-17
TW200944204A (en) 2009-11-01
JP5837128B2 (ja) 2015-12-24
AU2009224214B2 (en) 2013-12-12
CL2009000589A1 (es) 2010-03-26
RU2010141982A (ru) 2012-04-20
AR070816A1 (es) 2010-05-05
WO2009113741A3 (en) 2010-04-29
BRPI0909291A2 (pt) 2015-08-11
JP2014159458A (ja) 2014-09-04
US20110015224A1 (en) 2011-01-20
CN104906097A (zh) 2015-09-16
CN102026638B (zh) 2015-06-24
US20150150865A1 (en) 2015-06-04
US8980919B2 (en) 2015-03-17
BRPI0909291A8 (pt) 2016-07-12
JP5574989B2 (ja) 2014-08-20
AU2009224214A1 (en) 2009-09-17
EP2254578A2 (en) 2010-12-01
CN102026638A (zh) 2011-04-20
WO2009113741A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
AR066664A1 (es) Un medicamento para tratar enfermedad de alzheimer
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
MX378433B (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CR9667A (es) Derivados de benzamida y usos relacionados con los mismos
GT200900123A (es) Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace
HN2008001374A (es) Compuestos de cinamida policiclicos
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
AR048712A1 (es) Empleo de amidas de acidos alquilcarboxilicos como favorecedores de la penetracion
BR112013020270A2 (pt) derivados de pirazol microbicidas
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
DOP2011000231A (es) Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
AR067993A1 (es) Forma galenica divisible que permite una liberacion modificada del principio activo
ES2566162T3 (es) Composiciones de trometamina ketorolaco para tratar o prevenir el dolor ocular
PA8566301A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
EA200970947A1 (ru) Антиангиогенные агенты и способы их применения
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
GT200800102A (es) Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace
BR112015022849A2 (pt) sais de adição de base de nitroxolina e usos dos mesmos
UY30585A1 (es) Derivados de isoserina como inhibidores del factor ixa de la coagulacion
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
BR112015004813A8 (pt) composição de sabão, método de desinfecção de uma superfície e utilizações de uma composição

Legal Events

Date Code Title Description
FD Application declared void or lapsed